Abstract
The anticancer effects of combined gemcitabine and birinapant were demonstrated as synergistic in PANC-1 cells in vitro. In this study, pharmacokinetic information derived from experiments and the literature was utilized to develop full physiologically-based pharmacokinetic (PBPK) models that characterize individual drugs. The predicted intra-tumor drug concentrations were used as the driving force within a linked PBPK/PD model for treatment-mediated changes in tumor volume in a xenograft mouse model. The efficacy of the drug combination in vivo was evaluated mathematically as exhibiting additivity. The network model developed for drug effects in the in vitro cell cultures was applied successfully to link the in vivo tumor drug concentrations with tumor growth inhibition, incorporating more mechanistic features and accounting for disparate drug interaction outcomes in vitro and in vivo.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30. https://doi.org/10.3322/caac.21332
Eli Lilly and Company, Indianapolis I (1996) GEMZAR
Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS (2005) Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65:6835–6842. https://doi.org/10.1158/0008-5472.CAN-04-2246
Wong A, Soo RA, Yong W-P, Innocenti F (2009) Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41:77–88. https://doi.org/10.1080/03602530902741828
Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (2006) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849–855
Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JHM (2008) Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 36:1606–1615. https://doi.org/10.1124/dmd.108.021048
Benetatos CA, Mitsuuchi Y, Burns JM, Neiman EM, Condon SM, Yu G, Seipel ME, Kapoor GS, Laporte MG, Rippin SR, Deng Y, Hendi MS, Tirunahari PK, Lee Y-H, Haimowitz T, Alexander MD, Graham MA, Weng D, Shi Y, McKinlay MA, Chunduru SK (2014) Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 13:867–879. https://doi.org/10.1158/1535-7163.MCT-13-0798
Bai L, Smith DC, Wang S (2014) Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther 144:82–95. https://doi.org/10.1016/j.pharmthera.2014.05.007
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB (2014) Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 32:3103–3110. https://doi.org/10.1200/JCO.2013.52.3993
Tolcher A, Papadopoulos K, Patnaik A, Fairbrother W, Wong H, Budha N, Darbonne W, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera C, Bendell J, Burris H, Tolcher JI, Papadopoulos K, Patnaik A, Fairbrother W, Wong H, Budha N, Darbonne W, Peale F, Mamounas M, Royer-Joo S, Yu R, Portera C, Bendell J, Burris H, Infante J (2013) Abstract 2503: phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients with refractory solid tumors or lymphoma. 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, 31:2503
Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C (2015) Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol 75:851–859. https://doi.org/10.1007/s00280-015-2709-8
Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA (2015) A phase 1 study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.mct-15-0475
Zhu X, Straubinger RM, Jusko WJ (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42:477–496. https://doi.org/10.1007/s10928-015-9429-x
Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ (2018) Multi-scale network model supported by proteomics for analysis of combined gemcitabine and birinapant effects in pancreatic cancer cells. CPT Pharmacometrics Syst Pharmacol (in press)
Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ (2018) Proteomic analysis of combined gemcitabine and birinapant in pancreatic cancer cells. Front Pharmacol 9:84. https://doi.org/10.3389/fphar.2018.00084
Trueman SA, Ma WW, Straubinger RM (2016) Optimization of stromal modulation and drug-transporter interactions of a dovitnib/gemcitabine combination regimen in pancreatic cancer models. In: American association for cancer research conference-engineering and physical sciences in oncology, Boston, MA, 25–26 June 2016
Wang H, Li M, Rinehart JJ, Zhang R (2004) Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 10:1633–1644. https://doi.org/10.1158/1078-0432.CCR-0829-3
Moore MM, Estrada VA, Nieves FE, Burns JM, Mitsuuchi Y, Chunduru SK, Graham MA, McKinlay MA, Tolcher AW, Wick MJ (2009) Abstract B163: pharmacokinetic analysis and preclinical evaluation of the SMAC mimetic TL32711 in an orthotopic human breast tumor xenograft model. Mol Cancer Ther 8:B163. https://doi.org/10.1158/1535-7163.TARG-09-B163
Ma WW, Zhang H, Hylander B, LeVea C, Repasky E, Weng D, Burns J, Chunduru S, Graham M, Fetterly G, McKinlay M, Adjei A (2012) Abstract 1939: TL32711, a novel Smac mimetic, exerts significant antitumor efficacy in primary pancreatic adenocarcinoma model. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Ph. Cancer Res 72:1939. https://doi.org/10.1158/1538-7445.am2012-1939
Baxter LT, Zhu H, Mackensen DG, Jain RK (1994) Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54:1517–1528
Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407–484
Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ (2013) Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol 71:1219–1229. https://doi.org/10.1007/s00280-013-2116-y
Rodgers T, Leahy D, Rowland M (2005) Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259–1276. https://doi.org/10.1002/jps.20322
La H, Halladay JS, Shin Y, Wong S, Plise E, Chan OH, Flygare J, Fairbrother W, Wong. H (2010) Abstract P136: preclinical pharmacokinetic assessment of GDC-0152, a selective antagonist of the Inhibitor of Apoptosis (IAP) Proteins. 9th Int Soc Study Xenobiotics Meet Drug Discov Dev Istanbul, Turkey
Zhang T, Li Y, Zou P, Yu J, McEachern D, Wang S, Sun D (2013) Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharm Drug Dispos 34:348–359. https://doi.org/10.1002/bdd.1850
D’Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software
Amaravadi RK, Senzer NN, Martin LP, Schilder RJ, Lorusso P, Papadopoulos KP, Weng DE, Graham M, Adjei AA (2013) Abstract 2504: a phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J Clin Oncol 31:2504
Fetterly GJ, Liu B, Senzer NN, Amaravadi RK, Schilder RJ, Martin LP, Lorusso P, Papadopoulos KP, Adjei AA, Zagst PD, Mckinlay MA, Weng DE, Graham M, Park R, Cancer MC (2012) Abstract 3029: clinical pharmacokinetics of the smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. J Clin Oncol 30:3029
Nishikawa Y, Tsuji Y, Isoda H, Kodama Y, Chiba T (2014) Perfusion in the tissue surrounding pancreatic cancer and the patient’s prognosis. Biomed Res Int 2014:648021. https://doi.org/10.1155/2014/648021
Bouffard DY, Laliberté J, Momparler RL (1993) Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45:1857–1861
Ebrahem Q, Mahfouz RZ, Ng KP, Saunthararajah Y (2012) High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget 3:1137–1145. https://doi.org/10.18632/oncotarget.597
Sugiyama E, Kaniwa N, Kim S-R, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J-I (2010) Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 49:549–558. https://doi.org/10.2165/11532970-000000000-00000
Zhang L, Sinha V, Forgue ST, Callies S, Ni L, Peck R, Allerheiligen SRB (2006) Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33:369–393. https://doi.org/10.1007/s10928-006-9010-8
Kuenen BC, Rosen L, Smit EF, Parson MRN, Levi M, Ruijter R, Huisman H, Kedde MA, Noordhuis P, van der Vijgh WJF, Peters GJ, Cropp GF, Scigalla P, Hoekman K, Pinedo HM, Giaccone G (2002) Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657–1667
Kazmi F, Hensley T, Pope C, Funk RS, Loewen GJ, Buckley DB, Parkinson A (2013) Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos 41:897–905. https://doi.org/10.1124/dmd.112.050054
Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N, Werner J (2012) Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 12:226. https://doi.org/10.1186/1471-2407-12-226
Nolan-Stevaux O, Tedesco D, Ragan S, Makhanov M, Chenchik A, Ruefli-Brasse A, Quon K, Kassner PD (2013) Measurement of cancer cell growth heterogeneity through lentiviral barcoding identifies clonal dominance as a characteristic of in vivo tumor engraftment. PLoS ONE. https://doi.org/10.1371/journal.pone.0067316
Trédan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454. https://doi.org/10.1093/jnci/djm135
Acknowledgements
This work was supported by National Institutes of Health Grants R01 GM24211 to WJJ and R01 CA198096 to RMS. We thank Tetralogic Pharmaceuticals Inc. for sharing the information for the tumor growth study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhu, X., Trueman, S., Straubinger, R.M. et al. Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts. J Pharmacokinet Pharmacodyn 45, 733–746 (2018). https://doi.org/10.1007/s10928-018-9603-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10928-018-9603-z